Vaccine trial for advanced colorectal cancer with liver spread
Part of Cancer, Digestive system clinical trials.
This trial tests a new vaccine (YMN-136) for people with colorectal cancer that has spread to the liver and hasn't responded to at least three prior treatments. The goal is to see if the vaccine can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has spread to your liver and has progressed after at least three different treatment lines.
- You are between 18 and 75 years old.
- You are in good enough health to have a performance status of 0 or 1 (you're fully active or only slightly limited).
- Your blood counts and organ function must be within certain levels (your doctor will check this).
- You have not had a vaccine therapy before and can avoid live vaccines during the trial.
- You agree to use effective birth control if you are able to have children.
- You do not have other serious medical conditions (like uncontrolled infections, autoimmune diseases, or heart problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine therapy for people with advanced colorectal or small bowel cancer that has spread or can't be removed. The vaccine targets a protein found on cancer cells to help your immune system fight the cancer.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a personalized vaccine made from your own tumor cells for advanced colorectal cancer that is mismatch repair proficient (pMMR). It aims to see if the vaccine can help when standard treatments have stopped working.
This trial tests an investigational drug for colorectal cancer that has spread to the liver. It is designed for patients whose cancer hasn't responded to standard treatments and who have a specific genetic profile (pMMR).
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.